Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which offset a decline in its medical-device business, particularly in surgery revenue. Despite mixed segment results, J&J raised its full-year earnings guidance, signaling confidence in its future financial performance. Investors will watch how the company advances its medical-device innovations, including the OTTAVA project, to strengthen this area.
As of Oct 13, 2026 20:43 WIB, Johnson & Johnson shares trade at USD 253.73 on Pluang, down 3.79% for the day. Despite the recent earnings beat and raised guidance, the stock has seen more selling pressure with 84% of order activity on Pluang being sell orders. The company's market capitalization stands at $635.56 billion, reflecting its large scale in the health sector.
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's d...
As of October 2026, U.S. Treasury bills yield between 3.98% and 4.44% depending on maturity, surpassing Johnson & Johnson's 2.05% dividend yield. Treasury bills guarantee fixed returns until maturity but carry reinvestment and inflation risks, while ...
Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong per...
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
